These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38501355)

  • 1. Impact of the phenotypic expression of temocillin resistance in Escherichia coli on temocillin efficacy in a murine peritonitis model.
    Mallart E; Guerin F; Amoura A; Le Scouarnec M; Hamon A; El Meouche I; Chau F; Lefort A; Fantin B; Cattoir V; de Lastours V
    J Antimicrob Chemother; 2024 May; 79(5):1051-1059. PubMed ID: 38501355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli.
    Berleur M; Guérin F; Massias L; Chau F; Poujade J; Cattoir V; Fantin B; de Lastours V
    J Antimicrob Chemother; 2018 Nov; 73(11):3074-3080. PubMed ID: 30085154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inoculum effect of Escherichia coli expressing mcr-1 or not on colistin activity in a murine model of peritonitis.
    Fantin B; Poujade J; Grégoire N; Chau F; Roujansky A; Kieffer N; Berleur M; Couet W; Nordmann P
    Clin Microbiol Infect; 2019 Dec; 25(12):1563.e5-1563.e8. PubMed ID: 31494253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
    Soubirou JF; Rossi B; Couffignal C; Ruppé E; Chau F; Massias L; Lepeule R; Mentre F; Fantin B
    J Antimicrob Chemother; 2015 May; 70(5):1466-72. PubMed ID: 25564564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli.
    Alexandre K; Chau F; Guérin F; Massias L; Lefort A; Cattoir V; Fantin B
    J Antimicrob Chemother; 2016 Jul; 71(7):1899-904. PubMed ID: 27029848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates.
    Alexandre K; Soares A; Chau F; Fantin B; Caron F; Etienne M
    J Antimicrob Chemother; 2019 May; 74(5):1323-1326. PubMed ID: 30689887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the combination of colistin and fosfomycin against NDM-1-producing Escherichia coli with variable levels of susceptibility to colistin and fosfomycin in a murine model of peritonitis.
    Le Menestrel A; Guerin F; Chau F; Massias L; Benchetrit L; Cattoir V; Fantin B; de Lastours V
    J Antimicrob Chemother; 2021 Dec; 77(1):155-163. PubMed ID: 34718597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temocillin Resistance in the Enterobacter cloacae Complex Is Conferred by a Single Point Mutation in BaeS, Leading to Overexpression of the AcrD Efflux Pump.
    Guérin F; Gravey F; Reissier S; Penven M; Michaux C; Le Hello S; Cattoir V
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0035823. PubMed ID: 37195180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of two-component systems EnvZ/OmpR and BaeS/BaeR in in vitro temocillin resistance in Escherichia coli.
    Pérez-Palacios P; Rodríguez-Ochoa JL; Velázquez-Escudero A; Rodríguez-Baño J; Rodríguez-Martínez JM; Pascual Á; Docobo-Pérez F
    J Antimicrob Chemother; 2024 Mar; 79(3):641-647. PubMed ID: 38305703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
    Guillard T; Cambau E; Chau F; Massias L; de Champs C; Fantin B
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5830-5. PubMed ID: 24018262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum β-lactamase producing Escherichia coli in a mouse model.
    Chenouard R; Mahieu R; Luque Paz D; Marion E; Eveillard M; Dubée V
    PLoS One; 2021; 16(3):e0248177. PubMed ID: 33690674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine bloodstream infection models.
    Frimodt-Møller N; Hansen JU; Plattner M; Huseby DL; Radmer Almind S; Haldimann K; Gysin M; Petersson A; Ercan O; Ganz L; Hughes D; Vingsbo Lundberg C; Hobbie SN
    Int J Antimicrob Agents; 2024 Jul; 64(1):107181. PubMed ID: 38653351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of temocillin for phenotypic carbapenemase screening of Escherichia coli and Salmonella enterica isolates in relation to the presence of genes encoding ESBLs and carbapenemase production.
    Cavaco LM; Hansen F; Mushtaq S; Hill RLR; Woodford N; Le Hello S; Hendriksen RS; Hammerum AM; Hasman H
    J Antimicrob Chemother; 2019 Mar; 74(3):639-644. PubMed ID: 30544192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of temocillin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France.
    Duployez C; Loïez C; Cattoen C; Wallet F; Vachée A
    Med Mal Infect; 2019 Feb; 49(1):47-53. PubMed ID: 30396720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of temocillin and comparators against urinary Escherichia coli and Klebsiella pneumoniae from Iran.
    Rahbar M; Van de Velde S; Eslami P; Mardani M
    Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1793-1796. PubMed ID: 32333223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
    Machuca J; Ortiz M; Recacha E; Díaz-De-Alba P; Docobo-Perez F; Rodríguez-Martínez JM; Pascual Á
    J Antimicrob Chemother; 2016 Nov; 71(11):3066-3071. PubMed ID: 27494906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
    Canovas J; Petitjean G; Chau F; Le Monnier A; Fantin B; Lefort A
    Clin Microbiol Infect; 2020 Oct; 26(10):1416.e5-1416.e9. PubMed ID: 32629024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
    Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
    Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of Temocillin in Neutropenic Murine Infection Models.
    Muller AE; Raaphorst M; van der Meijden A; de Winter BCM; Meletiadis J; van den Berg S
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0143322. PubMed ID: 36692307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.